Skip to content
HOME about

A leading pioneer in leveraging iPSC innovation for drug discovery and regenerative medicine

The catalyst with the requisite iPSC know-how and experience to empower innovators to advance their science relentlessly.

Get Started

A snapshot of Ncardia

For the past decade at Ncardia, our team has collaborated with a broad array of clients to forge ahead their drug discovery programs for cardiovascular and neurological diseases. Throughout that process, they’ve leveraged our human iPSC products and services to increase their probability of downstream success in the discovery and development of new therapies. At Ncardia, we lean into advanced technology, so we can provide the right solutions: high-quality cells, relevant screening assays and robust iPSC differentiation processes for drug discovery and regenerative medicine.

Mission

To enable therapeutic developers harness the full potential of iPSCs with the goal of enhancing clinical success of their therapies

Vision

Capitalize on the unique value only iPSCs can deliver to revolutionize drug discovery and regenerative medicine

Ncardia Team

Meet the Ncardia team

At Ncardia, our innovative technologies are in the hands of a diverse team of expert scientists and strategists who are singularly focused on iPSCs – and who are committed to helping our clients solve critical problems, embrace bold yet highly strategic risks, and unlock the full potential of their discoveries.

Find out more   

Our milestones to-date

Our organization was foun only two years after the discovery of iPSCs. We have a singular focus to help realize the potential of this technology to advance human health. 

NCardia history Pluriomics
2011

Formulation of Pluriomics, an iPSC-derived research product company, by Stefan Braam and Herman Spolders, together with the scientific founders Prof. Dr. Mummery and Prof. Dr. Passier.

NCardia history iPSC screening
2016

First iPSC-based drug discovery screening activities performed

Ncardia history formation NCardia
2017

Ncardia was formed in August 2017 following an acquisition by Pluriomics

NCardia history launch large scale iPSC platform
2019

Launch of Ncardia’s large-scale iPSC manufacturing platform

NCardia history strategic partnership Kiniciti
2021

$60 million investment as part of a strategic partnership with Kiniciti to expand our drug discovery offerings

NCardia history affiliate company Cellistic
2022

Cellistic, an affiliate company focused on iPSC-based cell therapy, is formed to capitalize on Ncardia’s large-scale manufacturing expertise and proven processes in iPSC differentiation

NCAR-24-012c-NFI_JH Oortweg 21 _ 2024-0220
2023

Ncardia moves into new, larger offices - providing space for our growing team, doubling our lab area and quadrupling bioreactor capacity - to expand capabilities and facilitate longer and more comprehensive programs. 

What we value at Ncardia

We believe you should know what we stand for, since the code we live by in Ncardia’s offices and labs directly reflects how we partner with you and your team everywhere.

Solution-oriented
We focus on thoughtful yet efficient problem-solving, to benefit one another and our customers.

Innovative and collaborative-driven
We continually improve every aspect of what we do.  We were good yesterday; today, we’ll be even better.

Adaptable
The industry changes rapidly, so we maintain a highly flexible posture to evolve with it or ahead of it.

Dependable
Our clients have come to highly value our reliability: Put simply, we say what we do and we do what we say. 

 

A better way forward starts here

We’re committed to bringing our best to every project. Let’s find out what that would look like for your team through an initial discussion about your drug discovery goals.

Jeroen de Groot Divisional CEO
Jeroen de Groot 2